DarolutamideApalutamideenzalutamideARASENSandrogen deprivation therapynmCRPC
…metastatic hormone-sensitive prostate cancer (mHSPC) (ARASENS). Darolutamide was commercialised in 2020.Aim and Objectives To evaluate the t…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 45 of 2459Simple Clinical Colitis Activity IndexfilgotinibtofacitinibUlcerative colitisupadacitinibinfliximabadalimumabJAKi
…mitant mAb therapy. Effectiveness was assessed by clinical (CR; Simple Clinical Colitis Activity Index(SCCAI)≤3) and biochemical remission(BR; C-reactive protein(CRP)…
eptinezumabnational health systemCMMMDbotulinum toxinHFEMchronic migraine
…(≥15 MMD) or HFEM (10-15 MMD) who received at least one dose of eptinezumab at our hospital between April 24 and June 25.The following data…
upadacitinibtofacitinibfilgotinibrheumatoid arthritisbaricitinibulcerative colitisankylosing spondylitispsoriatic arthritisCrohn’s diseaseRA+4 more
… two JAKi, and another 7% have received three. Drugs used were: upadacitinib (40%), baricitinib (35%), tofacitinib (24%), and filgotinib (11…
ceftazidimeanidulafunginertapenemcefepimeceftolozanepiperacillinamikacinmeropenemaztreonamvancomycin
….7), piperacillin 59.15 (22.1–59.4), cefepime 64.8 (29.9–99.7), ceftazidime 59.4 (32.6–73.2); single values: ceftolozane 53.4, aztreonam 36…
BelimumabRituximabAnifrolumab
…mean current age of 45.3 years. Biologic therapies consisted of Belimumab in 47 patients (56.0%), Anifrolumab in 26 (31.0%), and Rituxima…
SLErituximabglucocorticoidsLupusNet
…Objectives The management of SLE varies worldwide. Current SLE treatment goals focus on controlling disease activity and preve…
cSLEprednisonebelimumabBELBEL-treatedJULES registry
…s an achievable goal in cSLE.To describe the characteristics of cSLE patients treated with BEL in real world practice included in th…
systemic lupus erythematosushydroxychloroquineSLEHCQHydroxychloroquineConclusions
… years vs. <3 years.Abstract PT6:02 Table 1Associations between systemic lupus erythematosus and heart failure and cardiomyopathyAbstract PT6:02 Figure 1Ris…
tuberculosisscarlet feverpertussismeaslesrubellainfluenza
…epidemiological study was conducted to analyse the incidence of tuberculosis, scarlet fever, pertussis, measles, influenza, mumps, varicella…
hydroxychloroquineiguratimodIGUSjögren’s syndromepSSHCQSSRI-30
…imed to compare the efficacy and safety of iguratimod (IGU) and hydroxychloroquine (HCQ) in patients with active primary Sjögren’s syndrome (pSS).…
dabrafenibBRAF-mutant advanced melanomaatezolizumabcobimetinibbinimetinibtrametinibnivolumabvemurafenibencorafenibrelatlimab+4 more
…(NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vem…